Body mass indices and outcome in patients with chronic heart failure
ABSTRACT There is an inverse relation between body mass and mortality in large populations of patients with chronic heart failure with a broad range of disease severity. The best measure of body size to describe the relation is not clear.
Patients with chronic heart failure (n = 2271, age 71.9 ± 11.3 years; 74.6% male) due to left ventricular systolic dysfunction were followed for a median of 1785 days (inter-quartile range, 874-2311 days) in survivors. We measured body mass index (BMI: weight/height²), ponderal index (PI: weight/height³), and body surface area (BSA). In a subset of 1025 patients, we also calculated the 'Charles index' [weight/(waist² × height)] together with bioimpedance data. During follow-up, 912 patients died. Measures of body mass were strong univariable predictors of outcome, and BSA (χ² = 71.3) was the strongest predictor followed by height (χ² = 68.6), weight (χ² = 57.4), then BMI (χ² = 15.2). The larger the patient's size, the lower the risk of mortality. Body surface area was the single strongest predictor of outcome in a multivariable model including 14 variables. In the subset with bioimpedance data, basal metabolic rate, BSA, weight, BMI, percentage body fat, fat mass, PI, and fat-free mass were all univariable predictors of outcome.
Measures of body size are strongly related to outcome in patients with chronic heart failure. Body surface area is a stronger predictor of mortality than other measures of body habitus, irrespective of height correction. The greater the overall bulk of the body, the better the survival.
- Pharmacology [?] Therapeutics 01/1979; 6(1):41-98. DOI:10.1016/0163-7258(79)90056-1 · 7.75 Impact Factor
- European Journal of Heart Failure 02/2011; 13(2):130-2. DOI:10.1093/eurjhf/hfq237 · 6.58 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Cancer and HIV infection/AIDS are associated with an increased risk of undernutrition and cachexia. During the past decade, patients became older, frequently overweight or obese and sedentary, conditions which are likely to result in fat-free mass (FFM) loss. This review sustains the hypothesis that FFM measurement should be implemented in routine clinical practice, to optimize the management of cancer and AIDS, as well as disease-related undernutrition. Undernutrition and FFM loss are associated with worse clinical outcome and increased therapy toxicity in cancer and AIDS patients. The emergence of the concept of sarcopenic obesity in cancer patients, a condition associated with decreased survival, demonstrates the necessity to assess their body composition with easily available methods, such as dual energy X-ray absorptiometry, computerized tomography and bioelectrical impedance analysis. FFM measurement could be helpful for guiding the choice of both disease-specific and nutritional therapies and for evaluating their efficacy and putative toxicity. FFM measurement at different steps of disease course could allow improving the guidance and efficacy of both cancer and HIV/AIDS-specific and nutritional therapies. The repeated measurement of FFM could allow reducing undernutrition-related morbidity, mortality and global healthcare costs, and could improve response and tolerance towards therapy, and quality of life.03/2011; 14(3):261-7. DOI:10.1097/MCO.0b013e3283455d60